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OBJECTIVES This study sought to assess the effect of angiotensin-converting enzyme (ACE) inhibitors and
beta-blockers on all-cause mortality in patients with left ventricular (LV) systolic dysfunction
according to gender, race, and the presence of diabetes.
BACKGROUND Major randomized clinical trials have established that ACE inhibitors and beta-blockers have
life-saving benefits in patients with LV systolic dysfunction. Most patients enrolled in these
trials were Caucasian men. Whether an equal effect is achieved in women, non-Caucasians,
and patients with major comorbidities has not been established.
METHODS The authors performed a meta-analysis of published and individual patient data from the 12
largest randomized clinical trials of ACE inhibitors and beta-blockers to produce random
effects estimates of mortality for subgroups.
RESULTS Data support beneficial reductions in all-cause mortality for the use of beta-blockers in men
and women, the use of ACE inhibitors and some beta-blockers in black and white patients,
and the use of ACE inhibitors and beta-blockers in patients with or without diabetes.
Women with symptomatic LV systolic dysfunction probably benefit from ACE inhibi-
tors, but women with asymptomatic LV systolic dysfunction may not have reduced
mortality when treated with ACE inhibitors (pooled relative risk  0.96; 95% confidence
interval: 0.75 to 1.22). The pooled estimate of three beta-blocker studies supports a
beneficial effect in black patients with heart failure, but one study assessing bucindolol
reported a nonsignificant increase in mortality.
CONCLUSIONS Angiotensin-converting enzyme inhibitors and beta-blockers provide life-saving benefits
in most of the subpopulations assessed. Women with asymptomatic LV systolic
dysfunction may not achieve a mortality benefit when treated with ACE inhibitors. (J Am
Coll Cardiol 2003;41:1529 –38) © 2003 by the American College of Cardiology
Foundation
Heart failure (HF) is a common medical condition that has
a significant impact on public health. In the U.S., an
estimated 4.8 million individuals are affected by HF, and
400,000 to 700,000 new cases develop each year (1). Heart
failure is associated with substantial morbidity and mortal-
ity; it is a primary or secondary cause of death for approx-
imately 250,000 people per year in the U.S. (2). According
to the 2002 Heart and Stroke Statistical Update (2), HF was
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the first-listed diagnosis for 962,000 hospitalizations in
1999, and it is the most common diagnosis among hospital
patients age 65 years and older.
A series of randomized clinical trials have established that
angiotensin-converting enzyme (ACE) inhibitors and beta-
adrenergic blocking agents (also called beta-blockers) pro-
vide life-saving benefits in patients with HF or left ventric-
ular (LV) systolic dysfunction. However, most of the
patients enrolled in such studies have been Caucasian males.
An important clinical question is whether the mortality
benefit reported in these clinical trials is also achieved for
other subpopulations, including women, non-Caucasians,
and patients with selected comorbidities, such as diabetes
mellitus.
There are several reasons to suspect that certain subpopu-
lations might not experience the same benefits as white
males. There is evidence that ACE inhibitors exert a lesser
effect on blood pressure in black compared with nonblack
hypertensive patients (3), and one of the ACE inhibitor
trials reported a lesser effect of ACE inhibitors on reducing
hospitalizations for black compared with nonblack patients
(4). Similarly, men and women may respond differently to
cardiac therapies. A preliminary analysis of one ACE
inhibitor study suggested a trend toward lower mortality
reduction in women compared with men (5). Because few of
the randomized trials enrolled a sufficient number of
women, blacks, or patients with comorbidities to have
sufficient statistical power to support conclusions based on
subgroup analyses, these important clinical questions are
appropriate for meta-analysis.
METHODS
We synthesized data from the 12 largest randomized trials
of ACE inhibitors and beta-blockers to test the hypotheses
of differences by gender, race, and comorbidities in reduc-
tion in all-cause mortality (Table 1) (6–24). Originally, we
had planned to synthesize data from all randomized trials of
these two drug classes that had at least 12 weeks duration of
follow-up and that reported mortality outcomes (25). We
performed an exhaustive literature search and identified 39
reports of randomized trials of ACE inhibitors and 35
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AIRE  Acute Infarction Ramipril Efficacy
BEST  Beta-blocker Evaluation of Survival
Trial
CI  confidence interval
CIBIS  Cardiac Insufficiency Bisoprolol
Study
CONSENSUS  Cooperative North Scandinavian
Enalapril Survival Study
COPERNICUS  Carvedilol Prospective Randomized
Cumulative Survival Study
HF  heart failure
HR  hazard ratio
LV  left ventricular
MERIT-HF  Metoprolol Extended-release
Randomized Intervention Trial in
Heart Failure
RR  relative risk
RRR  ratio of relative risks
SAVE  Survival And Ventricular
Enlargement
SMILE  Survival of Myocardial Infarction
Long-term Evaluation
SOLVD  Studies Of Left Ventricular
Dysfunction
TRACE  Trandolapril Cardiac Evaluation
Table 1. Sources of Data for Meta-Analysis From Principal
Randomized Clinical Trials of ACE Inhibitors and
Beta-Blockers
ACE Inhibitor Trial Name Source of Data
AIRE (10) Published data
CONSENSUS (8) Individual patient data
SAVE (16,19) Published data
SMILE (9) Published data
SOLVD (21,28) Individual patient data
TRACE (15) Individual patient data
Beta-Blocker Trial Name Source of Data
BEST (6,20,34) Published data
CIBIS-II (7,12) Published data
COPERNICUS (18) Individual patient data
MERIT-HF (13,14,22) Individual patient data
U.S. Carvedilol (17,23) Published data
ACE  angiotensin-converting enzyme. Trial acronyms as in Abbreviation Box.
Table 2. Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients
RR Analysis
Study
Name
Total
N
Male
N
Female
N
RR Male
(95% CI)
RR Female
(95% CI)
RRR
(95% CI)
CONSENSUS 253 179 74 0.61 (0.44–0.85) 1.14 (0.68–1.90) 1.86 (1.01–3.42)
SAVE 2,231 1,841 390 0.80 (0.68–0.95) 0.99 (0.67–1.47) 1.24 (0.80–1.90)
SMILE 1,556 1,128 428 0.61 (0.39–0.96) 0.74 (0.47–1.18) 1.22 (0.64–2.32)
SOLVD-Prevention 4,228 3,752 476 0.90 (0.77–1.05) 1.15 (0.74–1.78) 1.27 (0.80–2.02)
SOLVD-Treatment 2,569 2,065 504 0.89 (0.80–0.99) 0.86 (0.67–1.09) 0.97 (0.74–1.26)
TRACE 1,749 1,248 501 0.79 (0.68–0.91) 0.90 (0.74–1.11) 1.15 (0.90–1.48)
Random effects pooled estimate 10,213 2,373 0.82 (0.74–0.90) 0.92 (0.81–1.04) 1.15 (0.99–1.33)
ACE  angiotensin-converting enzyme; CI  confidence interval; RR  relative risk; RRR  ratio of relative risk. Trial acronyms as in Abbreviation Box.
1530 Shekelle et al. JACC Vol. 41, No. 9, 2003
Effect of ACE Inhibitors and Beta-Blockers in Subpopulations May 7, 2003:1529–38
reports of randomized trials of beta-blockers that reported
mortality outcomes and were of at least 12 weeks’ duration.
However, few studies published mortality outcomes strati-
fied by our subpopulations of interest, and data for most of
the smaller trials were not made available through contacts
with the study investigators. Therefore, we elected to seek
more intensive subpopulation data from the 12 largest
studies (Table 1). We calculated that the seven largest ACE
inhibitor studies (18 reports) enrolled 14,572 patients (83%
of total), whereas the remaining 19 ACE inhibitor trials (21
reports) enrolled an aggregate of 3,033 patients (17% of
total). Similarly, the five largest beta-blocker studies (15
reports) enrolled 12,727 patients (81% of total), whereas the
remaining 19 beta-blocker studies (20 reports) enrolled
Figure 1. Effect of angiotensin-converting enzyme inhibitors on mortality in patients with heart failure. For each study, the size of the box is proportional
to the sample size, and the lines denote the 95% confidence interval. For the combined result, the ends of the diamond shape denote the 95% confidence
interval. Trial acronyms defined in the Abbreviation Box. Prev  prevention; Tx  treatment.
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2,938 patients (19% of total). Therefore, most of the
statistical power to detect differences in subpopulations
resided in the few largest studies. By extracting published
data on subpopulations and by obtaining individual patient
data either from the original investigators or through the
Food and Drug Administration, we obtained a nearly
complete dataset for our meta-analysis.
Meta-analysis. The principal questions for meta-analysis
were as follows: 1) What are the associations between
treatment (ACE inhibitors or beta-blockers) and all-cause
mortality for male and female patients, patients with or
without diabetes, and black and white patients with HF? 2)
Do these associations vary (e.g., are there statistically
significant differences) by gender (female vs. male), diabetes
status (those with diabetes vs. those without), and race
(black vs. white patients)?
All reports that presented the relevant patient subpopu-
lation data did so in the form of two-by-two tables of
all-cause mortality by treatment group for each subpopula-
tion. Alternatively, if we were given the patient-level data,
we preferred to construct this table directly.
To answer our first question of interest, for each sub-
population (e.g., women), we estimated the log mortality
relative risk (RR), which is equal to the log of the risk of
dying for women who received ACE inhibitors divided by
the risk of dying for women who received placebo. The
standard error for the log RR was also estimated, and a 95%
confidence interval (CI) was constructed. We then back-
transformed to the unlogged scale for interpretability so that
our final statistic for each subpopulation in each study was
the RR with its associated CI. For subpopulations for which
we had data from at least three studies, we combined data
across studies using a random effects model (26).
To answer our second question, that is, whether the
Table 3. Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female
Patients Reported Separately for Prevention Studies and Treatment Studies
Analysis
RR Male
(95% CI)
RR Female
(95% CI)
RRR
(95% CI)
Treatment (symptomatic) studies 0.80 (0.68–0.93) 0.90 (0.78–1.05) 1.15 (0.88–1.51)
Prevention (asymptomatic) studies 0.83 (0.71–0.96) 0.96 (0.75–1.22) 1.25 (0.94–1.65)
Abbreviations as in Table 2.
Figure 2. Effect of angiotensin-converting enzyme inhibitors on mortality in male and female patients with heart failure (random effects pooled estimate).
For each study, the size of the box is proportional to the sample size, and the lines denote the 95% confidence interval. For the combined result, the ends
of the diamond shape denote the 95% confidence interval. Trial acronyms defined in Abbreviation Box.
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association differed between subpopulations (e.g., female vs.
male), we determined whether statistical differences existed
between the RRs for related subpopulations. To do this, a
test statistic equal to the ratio of relative risks (RRR) (which
equals the female RR divided by the male RR, patients with
diabetes RR divided by those without diabetes RR, or black
RR divided by white RR) was constructed. If this test
statistic differed significantly from one, then we inferred
that the two subgroup RRs are significantly different. As
before, we performed the analysis on the log scale, and we
then back-transformed the estimate and its CI to the
unlogged scale so that our final test statistic for each study
was the RRR. As before, we combined data across studies to
produce a pooled RRR. We tested whether this pooled
RRR was significantly different from one, which would
indicate a significant association between treatment effect
and subpopulation.
Because follow-up times varied across studies and calcu-
lating RR does not take this variation (or the censoring of
observations) into account, we also assessed the mortality
associated with ACE inhibitors and beta-blockers, respec-
tively, on the hazard ratio scale. The majority of our studies
presented hazard ratios (HRs) and CIs, and after transform-
ing these statistics to the log scale, we extracted the log HR
and its standard error for each study and subpopulation of
interest. We followed the same analytic strategy for the HR
as for the RR, conducting a random effects pooled analysis
to produce a pooled HR across studies. We then con-
structed a pooled ratio of HRs to compare the HRs in each
subpopulation. Hazard ratio results are presented when they
differed from the RR results.
For each drug and patient subpopulation comparison, we
assessed the possibility of publication bias by evaluating
funnel plots of the individual study log RRs and HRs,
respectively, and an adjusted correlation test (27) and a
regression asymmetry test (28). We found no evidence of
publication bias in any of the study subpopulations assessed.
In addition, we performed a sensitivity analysis, as studies
varied in their definitions of racial groups. For racial
comparisons, if the study provided data separately by racial
subgroup, we utilized these data. If data were not stratified
in that way, we used data for black versus nonblack patients.
Our last choice was data for nonwhite versus white patients.
The results of this sensitivity analysis did not differ markedly
from the primary conclusions.
RESULTS
ACE inhibitors. GENDER. We were able to obtain gender-
stratified data for all seven major studies to calculate the
effect of ACE inhibitors on mortality. The seven studies
were Cooperative North Scandinavian Enalapril Survival
Study (CONSENSUS), Survival And Ventricular Enlarge-
ment (SAVE), Studies Of Left Ventricular Dysfunction
(SOLVD) Prevention, SOLVD Treatment, Survival of
Myocardial Infarction Long-term Evaluation (SMILE),
Trandolapril Cardiac Evaluation (TRACE), and Acute
Infarction Ramipril Efficacy (AIRE). In aggregate, these
studies included 2,898 women and 11,674 men and lasted as
few as six months (CONSENSUS) to as many as 42
months (SAVE). The pooled random effects estimates from
the six studies with RR data yielded values for men of 0.82
(95% CI: 0.74 to 0.90) and for women of 0.92 (95% CI:
0.81 to 1.04). These results are displayed in Table 2 and
Figure 1. The corresponding pooled random effects esti-
mates from the six studies with HR data yielded values for
men of 0.76 (95% CI: 0.66, 0.87) and for women of 0.84
(95% CI: 0.72, 0.98). The difference in effect between men
and women approached statistical significance for the RRR
(p  0.07).
Table 4. Effect of ACE Inhibitors on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
RR Analysis
Study Name
Total
N
Nondiabetic
N
Diabetic
N
RR, Nondiabetic
(95% CI)
RR, Diabetic
(95% CI)
RRR
(95% CI)
CONSENSUS 253 197 56 0.64 (0.46–0.88) 1.06 (0.65–1.74) 1.67 (0.93–3.01)
SAVE 2,231 1,739 492 0.82 (0.68–0.99) 0.89 (0.68–1.16) 1.09 (0.79–1.50)
SMILE 1,556 1,253 303 0.79 (0.54–1.15) 0.44 (0.22–0.87) 0.56 (0.25–1.22)
SOLVD-Prevention 4,228 3,581 647 0.97 (0.83–1.15) 0.75 (0.55–1.02) 0.77 (0.54–1.09)
SOLVD-Treatment 2,569 1,906 663 0.84 (0.74–0.95) 1.01 (0.85–1.21) 1.21 (0.97–1.50)
TRACE 1,749 1,512 237 0.85 (0.74–0.97) 0.73 (0.57–0.94) 0.87 (0.65–1.15)
Random effects pooled estimate 10,188 2,398 0.85 (0.78–0.92) 0.84 (0.70–1.00) 1.00 (0.80–1.25)
Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box.
Table 5. Effect of ACE Inhibitors on Mortality From Heart Failure in Black and White Patients
Study Name
Total
N
White
N
Non-White
N
Black
N
Non-Black
N
RR White
(95% CI)
RR Black
(95% CI)
RRR
(95% CI)
SAVE 2,231 1,993 238 0.84 (0.71–0.99) 0.78 (0.50–1.21) 1.08 (0.67–1.73)
SOLVD-Prevention 4,228 3,657 571 404 3,824 0.95 (0.81–1.12) 0.87 (0.60–1.25) 0.91 (0.61–1.36)
SOLVD-Treatment 2,569 2,061 508 396 2,173 0.89 (0.79–1.00) 0.93 (0.74–1.17) 1.04 (0.81–1.35)
Random effects pooled estimate 7,711 1,317 800 5,997 0.89 (0.82–0.97) 0.89 (0.74–1.06) 1.01 (0.83–1.24)
Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box.
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In a post hoc subgroup analysis, studies were divided into
those treating symptomatic HF (CONSENSUS, SOLVD
Treatment, and TRACE) compared with those treating
asymptomatic LV systolic dysfunction (SAVE, SOLVD
Prevention, and SMILE). The pooled analysis included
1,079 women in the symptomatic HF studies and 1,294
women in the asymptomatic HF studies. Men clearly
benefit when treated with ACE inhibitors for either symp-
tomatic or asymptomatic LV systolic dysfunction. The
evidence indicates that women with symptomatic HF prob-
ably benefit when treated with ACE inhibitors, although
the benefit may be somewhat less than that seen in men (RR
 0.90; 95% CI: 0.78 to 1.05). A potential difference in
efficacy of ACE inhibitors between men and women in the
treatment of asymptomatic LV dysfunction was suggested.
In the studies analyzed, a significant mortality benefit for
women with asymptomatic LV dysfunction was not dem-
onstrated (RR  0.96; 95% CI: 0.75 to 1.22; Table 3 and
Fig. 2). These results are compatible with an earlier prelim-
inary analysis of the SOLVD data (5). However, the RRR
between men and women does not reach statistical signifi-
cance, so that a significant difference in response between
men and women cannot be concluded.
DIABETES. Six studies stratified data by diagnosis of diabe-
tes, permitting calculation of the differential effect of ACE
inhibitors on mortality. These studies were CONSENSUS,
SAVE, the two SOLVD studies, SMILE, and TRACE. In
aggregate, these studies included 2,398 patients with diabe-
tes and 10,188 patients without diabetes. All of these studies
contributed data to our RRs analysis; however, the SAVE
study did not contain data that we could use for our HRs
analysis. Both analyses yielded similar results. The random
effects pooled estimate of the RR of mortality in patients
with diabetes is 0.84 (95% CI: 0.70 to 1.00), whereas the
estimate of the RR in patients without diabetes is 0.85 (95%
CI: 0.78 to 0.92). These data are presented in Table 4. We
interpret these results as indicating that patients with
diabetes as well as those without diabetes achieve reductions
in mortality when treated with ACE inhibitors for HF.
RACE. Three studies provided data stratified by patient race
to assess the effects of ACE inhibitors on mortality. The
studies with appreciable numbers of black patients were
SAVE and the two SOLVD studies. The remaining ACE
inhibitor studies (AIRE, CONSENSUS, SMILE, and
TRACE) were conducted primarily in Scandinavian and
European countries and did not include substantial numbers
of black patients. The SAVE study did not present data that
allowed us to calculate the HRs, which left only two studies
(the SOLVD studies), an insufficient number to pool for
this analysis. Therefore, only a pooled RR analysis was
performed, which yielded an estimate in white patients of
0.89 (95% CI: 0.82 to 0.97) and an estimate in black
patients of 0.89 (95% CI: 0.74 to 1.06). These data are
presented in Table 5. Whereas the RR reduction in black
patients did not achieve conventional levels of statistical
significance, the estimate of effect is the same as the
statistically significant reduction seen in white patients.
Furthermore, the two estimates of effect (for black and
white patients) do not differ from each other statistically.
The most likely explanation for the lack of statistical
significance in the estimate for black patients is the much
smaller sample size, which increases the standard error and
95% CIs. We interpret these data as indicating that there is
no evidence that black patients achieve lesser or greater
reductions in mortality than white patients when treated
with ACE inhibitors for HF. These results are consistent
with the analysis by the SOLVD Investigators that there
was not a lesser reduction in mortality among black com-
pared with white patients in the SOLVD studies, although
these investigators did report a difference in hospitalization
rates in black patients compared with white patients (29).
Table 6. Effect of Beta-Blockers on Mortality From Heart Failure in Male and Female Patients
RR Analysis
Study-Name
Total
N
Male
N
Female
N
RR Male
(95% CI)
RR Female
(95% CI)
RRR
(95% CI)
CIBIS-II 2,647 2,132 515 0.71 (0.58–0.87) 0.52 (0.30–0.89) 0.73 (0.41–1.30)
COPERNICUS 2,287 1,822 465 0.68 (0.54–0.86) 0.63 (0.39–1.04) 0.93 (0.54–1.59)
MERIT-HF 3,991 3,093 898 0.63 (0.50–0.78) 0.93 (0.58–1.49) 1.49 (0.88–2.51)
U.S. Carvedilol HF 1,094 838 256 0.44 (0.24–0.82) 0.32 (0.11–0.93) 0.73 (0.21–2.51)
Random effects pooled estimate 7,885 2,134 0.66 (0.59–0.75) 0.63 (0.44–0.91) 0.99 (0.70–1.41)
Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box.
Table 7. Effect of Beta-Blockers on Mortality From Heart Failure in Diabetic and Nondiabetic Patients
Study Name
Total
N
Nondiabetic
N
Diabetic
N
RR,
Nondiabetic (95% CI)
RR,
Diabetic (95% CI)
RRR
(95% CI)
CIBIS-II 2,647 2,335 312 0.66 (0.54–0.81) 0.81 (0.52–1.27) 1.23 (0.75–2.02)
COPERNICUS 2,287 1,701 586 0.67 (0.52–0.85) 0.68 (0.47–1.00) 1.02 (0.65–1.61)
MERIT-HF 3,991 3,006 985 0.62 (0.48–0.79) 0.81 (0.57–1.15) 1.32 (0.86–2.02)
Random effects pooled estimate 7,042 1,883 0.65 (0.57–0.74) 0.77 (0.61–0.96) 1.19 (0.91–1.55)
Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box.
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Beta-blockers. GENDER. Five studies on the effects of
beta-blocker treatment on mortality stratified data by gen-
der. The studies were Cardiac Insufficiency Bisoprolol Study
(CIBIS)-II, Carvedilol Prospective Randomized Cumula-
tive Survival Study (COPERNICUS), Metoprolol
Extended-release Randomized Intervention Trial in Heart
Failure (MERIT-HF), Beta-blocker Evaluation of Survival
Trial (BEST), and U.S. Carvedilol. The CIBIS-II study
contributed data only to the RR analysis. Bucindolol, which
was the beta-blocker evaluated in BEST, was judged to be
potentially different in action from the other beta-blockers.
Therefore, pooled analyses were performed with and with-
out the inclusion of BEST. The BEST study contributed
data only to the HR analysis, which yielded a result similar
to the RR analysis, and only the RR analysis is presented
here. In aggregate, the pooled studies included 2,134
women and 7,885 men. Both analyses yielded similar
results. The random effects pooled estimate for the RR of
mortality for women was 0.63 (95% CI: 0.44 to 0.91),
whereas for men, the estimate was 0.66 (95% CI: 0.59 to
0.75). The corresponding values for the HR analysis were
0.75 (95% CI: 0.51 to 1.09) for women and 0.68 (95% CI:
0.51 to 0.89) for men. These data are presented in Table 6.
Our interpretation of these data is that women and men
with symptomatic HF have reduced mortality when treated
with beta-blockers.
DIABETES. Three studies stratified data by diagnosis of
diabetes, permitting calculation of the differential effect of
beta-blockers on mortality (CIBIS, COPERNICUS,
MERIT-HF). In aggregate, these studies included 1,883
patients with diabetes and 7,042 patients without diabetes.
The only pooled estimates that were possible were the RRs,
which yielded a value of 0.65 (95% CI: 0.57, 0.74) for
nondiabetic patients and a value of 0.77 (95% CI: 0.61,
0.96) for diabetic patients. This RRR was not statistically
significant. These data are presented in Table 7. Our
interpretation of these data is that patients with diabetes and
HF have reduced mortality when treated with beta-
blockers. It is possible that the relative reduction in mortal-
ity may be less for patients with diabetes than for those
without diabetes, but because the absolute risk of mortality
is greater in diabetic patients, the absolute risk reduction is
almost certainly equal or greater for diabetic than for
nondiabetic HF patients treated with beta-blockers.
RACE. We were able to obtain race-stratified data to assess
the effects of beta-blocker treatment on mortality in four
studies. These studies were BEST, COPERNICUS,
MERIT-HF, and U.S. Carvedilol. As noted above, bucin-
dolol was judged to be potentially clinically dissimilar to the
beta-blockers; therefore, pooled analyses were done with
and without the inclusion of BEST. The CIBIS-II study
was conducted in Scandinavian and European countries and
did not enroll appreciable numbers of black patients. In
aggregate, the four studies included in the pooled analysis
enrolled 1,172 black and more than 8,000 white patients.
Both the RR analysis and the HR analysis yielded similar
results. The pooled random effects estimate (including
BEST) of the RR of the effect on mortality for black
patients was 0.97 (95% CI: 0.68 to 1.37), whereas for white
patients, it was 0.69 (95% CI: 0.55 to 0.85). The pooled
random effects estimate (without BEST) of the RR of the
effect on mortality for black patients was 0.67 (95% CI: 0.38
to 1.16). These data are displayed in Table 8 and Figure 3.
Our interpretation of these data is that black patients are
likely to have the same RR reduction as white patients
treated with the beta-blockers bisoprolol, metoprolol, or
carvedilol. Although the results for black patients were not
statistically significant compared with placebo, the point
estimates of effect (without BEST) were similar to those in
white patients; therefore, we judge that the smaller sample
size is the most likely reason for this finding. In contrast,
bucindolol was associated with worse mortality outcomes in
black patients than in white patients, and is not effective in
decreasing mortality in blacks.
DISCUSSION
For most of the subpopulations assessed in our meta-
analysis, our results are reassuring in that we found evidence
supporting beneficial reductions in all-cause mortality with
the use of beta-blockers in men and women, the use of ACE
inhibitors in black and white patients, and the use of either
drug in patients with diabetes. However, we did find
evidence that women with asymptomatic LV dysfunction
Table 8. Effect of Beta-Blockers on Mortality From Heart Failure in Black and White Patients
RR Analysis
Study Name
Total
N
White
N
Non-White
N
Black
N
Non-Black
N
RR White
(95% CI)
RR Black
(95% CI)
RRR
(95% CI)
COPERNICUS 2,287 2,069 218 121 2,166 0.66 (0.53–0.82) 0.62 (0.19–2.01) 0.94 (0.28–3.11)
MERIT-HF 3,991 3,755 236 207 3,784 0.67 (0.54–0.82) 0.79 (0.36–1.76) 1.19 (0.52–2.70)
U.S. Carvedilol HF 1,094 217 877 0.38 (0.20–0.70) 0.53 (0.19–1.48) 1.41 (0.43–4.68)
BEST 2,708 627 2,081 0.85 (0.74–0.96) 1.17 (0.94–1.47) 1.39 (1.07–1.79)
Random effects pooled
estimate (with BEST)
5,824 454 1,172 8,908 0.69 (0.55–0.85) 0.97 (0.68–1.37) 1.35 (1.07–1.71)
Random effects pooled
estimate (without BEST)
5,824 454 545 6,827 0.63 (0.52–0.77) 0.67 (0.38–1.16) 1.17 (0.65–2.11)
Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box.
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may not have reduced mortality when treated with ACE
inhibitors, and additional study is needed to address this
issue.
We also found evidence supporting the beneficial effect of
beta-blocker use in black patients. For three of the beta-
blocker studies, the pooled estimate of effect suggested that
black patients and white patients have similar reductions in
all-cause mortality when treated with beta-blockers. How-
ever, one study, which was unique in that it assessed the
beta-blocker bucindolol, reported a statistically significant
adverse effect on mortality in blacks relative to whites. This
may be due in part to bucindolol’s partial agonist activity
(30), a property that has been associated with adverse
outcomes in patients with prior myocardial infarction (31)
Figure 3. Effect of beta-blockers on mortality in patients with heart failure. For each study, the size of the box is proportional to the sample size, and the
lines denote the 95% confidence interval. For the combined result, the ends of the diamond shape denote the 95% confidence interval. Trial acronyms
defined in Abbreviation Box.
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and in patients with HF (32). In any case, these results
suggest that the benefits of beta-blockers cannot be consid-
ered equivalent across the entire class of available agents.
Study limitations. Our meta-analysis has several potential
limitations common to most meta-analyses. We cannot
adjust for inherent biases in the individual studies, and in
some cases there was substantial between-study heteroge-
neity. The most important limitation specific to this analysis
is the inability to control for possible differences between
subpopulations in the etiology of HF. Women and blacks
are less likely than white males to have an ischemic etiology
of HF. In the SOLVD studies, for example, 27.7% of
women had nonischemic HF, as compared with 16.1% of
men (p  0.001) (33). Similarly, 40.9% of blacks had
nonischemic HF, as compared with only 14.6% of whites
(p  0.001) (33). It is possible that the benefits of ACE
inhibitors in HF are due in part to a vasculoprotective effect,
as suggested by the Heart Outcomes Prevention Evaluation
(HOPE) study (34). Likewise, the benefits of beta-blockers
may be due in part to their anti-ischemic effects. Further
research is needed to answer these questions.
Our findings suggest several important future research
studies. Additional data are needed to support or refute the
evidence that different beta-blockers may have different
effects on all-cause mortality in black patients. Future
studies of existing or new beta-blocker drugs for HF need to
include sufficient numbers of black patients to separately
assess outcomes in this population, as a similar effect in
black patients and white patients cannot be assumed.
A second area for future research is further assessment of
the effect of ACE inhibitors in women with asymptomatic
LV dysfunction. It may be possible to answer this question
by a more complete analysis of existing data from random-
ized clinical trials. This would require an individual patient
data meta-analysis, which in turn would require obtaining
individual patient data from all of the randomized trials.
Although such an effort would be costly, it would be
substantially less expensive and more ethical than mounting
a new clinical trial designed to answer this question. Until
additional data become available, we do not consider our
findings sufficient to warrant withholding ACE inhibitors
from asymptomatic women with reduced LV systolic func-
tion.
Additionally, other outcomes of interest should be exam-
ined for all patient subpopulations, including cardiac mor-
tality, symptoms, quality of life, and health care utilization.
There is also a need to examine other major subpopulations,
including the elderly and patients with impaired renal
function. Individual patient level data from the major
randomized clinical trials may be sufficient to answer these
questions, but published data are scant.
If our findings of differential efficacy in selected sub-
groups are confirmed, then additional research aimed at
identifying the cause for these disparities should be under-
taken. As noted above, one possibility is that these findings
do not represent differences in men or women or in black
patients or white patients, but rather reflect differing efficacy
of these drugs according to the cause of HF (e.g., ischemic
or nonischemic), which may differ by gender or race.
Alternatively, there could be a molecular basis for differ-
ences in response by gender and race.
Given the robust evidence of benefit for ACE inhibitors
and beta-blockers in reducing mortality, future work should
also focus on how to increase the use of these therapies by
addressing potential barriers for practitioners and patients.
In summary, meta-analysis of the major randomized
clinical trials of ACE inhibitors and beta-blockers in pa-
tients with HF and LV systolic dysfunction indicate that
these agents reduce all-cause mortality in men, whites,
diabetics, and nondiabetics. In addition, beta-blockers are
effective in women, ACE inhibitors are effective in blacks,
and, with the exception of bucindolol, beta-blockers are
effective in blacks. Angiotensin-converting enzyme inhibi-
tors are also effective in women with symptomatic HF, but
the data are inconclusive on the value of ACE inhibitors in
women with asymptomatic LV dysfunction. Although we
do not recommend changes in present treatment guidelines,
additional study is needed to evaluate the effects of ACE
inhibitors in women with asymptomatic LV dysfunction
and to determine the mechanisms underlying potential
differential effects of these agents in diverse patient popu-
lations.
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